CIA
CRDL

Concurrent Investment Advisors’s Cardiol Therapeutics CRDL Stock Holding History

Concurrent Investment Advisors’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.9K Buy
+25,387
New +$32.1K ﹤0.01% 2079

Other funds holding CRDL

PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
BFS
Boyer Financial Services Newport Beach, California $118M AUM
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
APW
Aurora Private Wealth Rockaway, New Jersey $158M AUM
PSB
Piscataqua Savings Bank Portsmouth, New Hampshire $148M AUM 32.61% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Concurrent Investment Advisors's CRDL Position: Q2 2026 in Review

Concurrent Investment Advisors opened a new position in Cardiol Therapeutics (CRDL) in Q2 2026: 25,387 shares worth $26.9K. The stake represents ﹤0.01% of the portfolio and ranks #2079 among its holdings.

8 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

  • Concurrent Investment Advisors held 25,387 shares of Cardiol Therapeutics worth $26.9K as of Q2 2026.
  • Cardiol Therapeutics was a new Concurrent Investment Advisors position in Q2 2026.
  • Cardiol Therapeutics made up ﹤0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #2079 holding.
  • 8 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.